TAHORA

• Research type

  Research Study

• Full title

  A Multi-national Real-world Outcomes and Treatment Patterns Study of Lanadelumab (Takhzyro) in Paediatric Patients with Hereditary Angioedema (TAHORA)

• IRAS ID

  367136

• Contact name

  Stephen Owens

• Contact email

  stephen.owens@nhs.net

• Sponsor organisation

  Takeda

• Clinicaltrials.gov Identifier

  EMEA/H/C/004806, EMEA

• Duration of Study in the UK

  0 years, 8 months, 16 days

• Research summary

  A Multi-national Real-world Outcomes and Treatment Patterns Study of Lanadelumab (Takhzyro) in Paediatric Patients with Hereditary Angioedema (TAHORA).This is an observational, multi-country, retrospective cohort study consisting of a medical chart review of paediatric patients (aged 2 to <12 years) with HAE-C1INH who initiated LTP treatment with lanadelumab within a routine clinical setting in Germany, France, the UK, Israel, Argentina, and Serbia (with potential expansion to additional countries). Approximately 40 patient charts are anticipated to be collected over an approximate 3-month period.

• REC name

  East of England - Cambridge Central Research Ethics Committee

• REC reference

  26/EE/0038

• Date of REC Opinion

  4 Feb 2026

• REC opinion

  Favourable Opinion